A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
HairClone aims to rejuvenate miniaturizing hairfollicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hairfollicles, but full regenerative treatments will take many years to develop.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hairfollicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
A human trial involving verteporfin for hairregeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Exercise, especially leg workouts, combined with finasteride and minoxidil, may enhance hair regrowth. Cold exposure, like cold showers, might further boost results.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hairregeneration.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hairfollicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
A trial of verteporfin for hairregeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
The conversation discusses verteporfin as a potential treatment for hairregeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hairregeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The conversation is about a hair loss treatment routine involving dermarolling, finasteride, minoxidil, and natural oils. Suggestions include using shorter needles for better absorption of treatments and longer needles less frequently for hair follicle regeneration.
The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hairfollicles without affecting the entire system.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hairfollicles.
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.
The conversation discusses the correct method of microneedling for hair loss, questioning whether it should be done on areas with long hair without risking hair damage, and if it's necessary for improving blood flow to existing hair. No specific treatments were mentioned.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
A user shared their experience with a Long Hair DHI Hair Transplant, receiving 2,750 grafts. They plan to continue using Dutasteride and Topical Minoxidil post-surgery.